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Aims: The prevalence of Alzheimer’s disease (AD) along with its social and economic burden continues 
to rise worldwide. Increasing evidence points towards smaller, pre-fibrillary aggregates, known as beta-
amyloid oligomers (oAβ), as the primary cause of disease. We identified TBC1D5 as an AD risk gene 
from multiple resampled GWAS in the Korean population followed by confirmational functional genomic 
screening in a Drosophila AD model. Further, we investigated the role of this key regulator of intracellular 
trafficking and vesicle transport in the clearance of oAβ in differentiated neuron-like cells. 
Methods: We established a stable cell line lacking TBC1D5 by selectively inhibiting the human 
orthologue of this endocytic gene using siRNA in differentiated neuron-like SH-SY5Y cells. We then 
investigated the effect of TBC1D5 knockdown on oAβ uptake, processing and clearance after 3, 24 and 
48 hours post-treatment with oAβ. 
Results: The levels of TBC1D5 are significantly reduced in the cortex of human AD patients’ brains 
compared to that of age-matched controls and is associated with temporal lobe atrophy. Knockdown of 
TBC1D5 also increases oAβ accumulation in neuronal-like cells, decreases clearance of oAβ internalised 
from extracellular milieu and increases Aβ-induced cytotoxicity. 
Conclusions: Our results suggest that endocytosis is a major cellular pathway associated with AD, and 
that down-regulation of molecular components of endocytic machinery may be involved in the 
pathological mechanisms underlying AD. Modulators of endocytic proteins, like TBC1D5, may serve as 
effective therapeutic targets to enhance the proper recycling and clearance of toxic oAβ to slow down 
disease progression. 
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Aims: Alzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved 
yet. This fact, together with the lack of reliable models, has impeded the development of effective 
therapies. Recently, several studies have shown that functional glial cell defects have a key role in the 
pathology of AD. However, this glial dysfunction, currently, cannot be correctly modeled using the 
available animal models, so we hypothesized that cells derived from Alzheimer's patients can serve as a 
better platform for studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the 
generation of different types of neural cells, which can be used for disease modeling, identification of new 
targets and drugs development. 
Methods: We have a collection of hiPSCs derived from patients with sporadic forms of AD. We have 
differentiated these cells towards neural lineage to obtain neurons and astrocytes. For the generation of 
oligodendrocytes (OLs), we have developed a fast and robust protocol to generate mature OLs in just 22 
days. 
Results: We have generated neural precursors from all the lines tested. In the case of OLs, the cells 
generated resemble primary OLs and can myelinate neurons in vivo and in vitro using a screening 
compatible platform. This platform is being transferred for the generation of the other glial cells. 
Conclusions: This methodology can be used to elucidate the pathogenic pathways associated with 
neurodegeneration and to identify new therapeutic targets susceptible to modulation, contributing to the 
development of new effective drugs against AD. 
 
